NeuroPace Statistics
Total Valuation
NeuroPace has a market cap or net worth of $351.27 million. The enterprise value is $358.16 million.
Important Dates
The next estimated earnings date is Tuesday, August 12, 2025, after market close.
| Earnings Date | Aug 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
NeuroPace has 32.80 million shares outstanding. The number of shares has increased by 12.30% in one year.
| Current Share Class | 32.80M |
| Shares Outstanding | 32.80M |
| Shares Change (YoY) | +12.30% |
| Shares Change (QoQ) | +5.24% |
| Owned by Insiders (%) | 3.64% |
| Owned by Institutions (%) | 53.41% |
| Float | 21.32M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.76 |
| Forward PS | 3.50 |
| PB Ratio | 14.30 |
| P/TBV Ratio | 14.47 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 4.25 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.63, with a Debt / Equity ratio of 3.01.
| Current Ratio | 6.63 |
| Quick Ratio | 5.55 |
| Debt / Equity | 3.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.22 |
Financial Efficiency
Return on equity (ROE) is -128.49% and return on invested capital (ROIC) is -13.03%.
| Return on Equity (ROE) | -128.49% |
| Return on Assets (ROA) | -11.52% |
| Return on Invested Capital (ROIC) | -13.03% |
| Return on Capital Employed (ROCE) | -20.18% |
| Revenue Per Employee | $458,185 |
| Profits Per Employee | -$134,810 |
| Employee Count | 184 |
| Asset Turnover | 0.81 |
| Inventory Turnover | 1.70 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +56.35% in the last 52 weeks. The beta is 2.04, so NeuroPace's price volatility has been higher than the market average.
| Beta (5Y) | 2.04 |
| 52-Week Price Change | +56.35% |
| 50-Day Moving Average | 12.70 |
| 200-Day Moving Average | 10.89 |
| Relative Strength Index (RSI) | 37.07 |
| Average Volume (20 Days) | 405,557 |
Short Selling Information
The latest short interest is 356,665, so 1.09% of the outstanding shares have been sold short.
| Short Interest | 356,665 |
| Short Previous Month | 355,768 |
| Short % of Shares Out | 1.09% |
| Short % of Float | 1.67% |
| Short Ratio (days to cover) | 0.71 |
Income Statement
In the last 12 months, NeuroPace had revenue of $84.31 million and -$24.81 million in losses. Loss per share was -$0.83.
| Revenue | 84.31M |
| Gross Profit | 63.08M |
| Operating Income | -19.27M |
| Pretax Income | -31.51M |
| Net Income | -24.81M |
| EBITDA | -19.06M |
| EBIT | -19.27M |
| Loss Per Share | -$0.83 |
Full Income StatementBalance Sheet
The company has $66.26 million in cash and $73.15 million in debt, giving a net cash position of -$6.89 million or -$0.21 per share.
| Cash & Cash Equivalents | 66.26M |
| Total Debt | 73.15M |
| Net Cash | -6.89M |
| Net Cash Per Share | -$0.21 |
| Equity (Book Value) | 24.27M |
| Book Value Per Share | 0.74 |
| Working Capital | 82.77M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$17.90 million and capital expenditures -$239,000, giving a free cash flow of -$18.14 million.
| Operating Cash Flow | -17.90M |
| Capital Expenditures | -239,000 |
| Free Cash Flow | -18.14M |
| FCF Per Share | -$0.55 |
Full Cash Flow StatementMargins
Gross margin is 74.83%, with operating and profit margins of -22.86% and -29.42%.
| Gross Margin | 74.83% |
| Operating Margin | -22.86% |
| Pretax Margin | -29.42% |
| Profit Margin | -29.42% |
| EBITDA Margin | -22.61% |
| EBIT Margin | -22.86% |
| FCF Margin | n/a |
Dividends & Yields
NeuroPace does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -12.30% |
| Shareholder Yield | -12.30% |
| Earnings Yield | -7.06% |
| FCF Yield | -5.16% |
Analyst Forecast
The average price target for NeuroPace is $15.14, which is 41.36% higher than the current price. The consensus rating is "Buy".
| Price Target | $15.14 |
| Price Target Difference | 41.36% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | 19.85% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
NeuroPace has an Altman Z-Score of -3.75 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.75 |
| Piotroski F-Score | 4 |